Multidimensional family therapy (MDFT) treatment of adolescents with substance use disorders, focusing on risk and protective factors in major youth life domains
Phase 2
Completed
- Conditions
- Cannabis abuse and cannabis dependenceMental and Behavioural DisordersMental and behavioural disorders due to use of cannabinoids
- Registration Number
- ISRCTN51014277
- Lead Sponsor
- Erasmus Medical Centre (Netherlands)
- Brief Summary
2010 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/20380718 2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24485347 2018 results in: http://www.ncbi.nlm.nih.gov/pubmed/30140308
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 480
Inclusion Criteria
1. Age of the adolescent 13 through 18 years, either sex
2. Diagnosis of cannabis use disorder
3. At least 1 parent willing to take part in the treatment programme
4. Informed consent by both adolescent and parent(s)
Exclusion Criteria
1. Disorder requiring hospitalisation or other residential treatment
2. Intelligence Quotient (IQ) of adolescent below 70
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. MDFT reduces cannabis consumption more strongly than TAU in the 90-day periods preceding follow-up assessments points (a lower number of consumption days: TLFB = TimeLine Follow Back), the difference growing bigger over time<br>2. Number of urine tests indicative of cannabis use is lower in MDFT than in TAU at follow-up assessments points<br>3. In MDFT, youth show fewer (symptoms of) diagnoses of cannabis use disorders (as measured with the Adolescent Diagnostic Interview-Light [ADI-Light]) than in TAU at 12 months follow-up (the validated ADI-Light measures symptoms of substance use disorders). Assessment points: baseline, 12 months follow up.
- Secondary Outcome Measures
Name Time Method